Propofol Versus Sevoflurane for Induction of GA in Infants
The Hemodynamic Effects of Propofol Versus Sevoflurane for Induction of Anesthesia in Healthy Infants as Measured by Electrical Cardiometry: Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Shymaa Fathy, MD
- Phone Number: 002 +201000455897
- Email: angel6122003@yahoo.com
Study Locations
-
-
-
Cairo, Egypt, 11562
- Recruiting
- Faculty of Medicine- Cairo University
-
Contact:
- Shymaa Fathy, MD
- Phone Number: 002 23649281
- Email: pg@kasralainy.edu.eg
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- infants aged 3 months or less scheduled for elective surgery
Exclusion Criteria:
- significant structural congenital heart disease
- intracranial malformation.
- preexisting hemodynamic instability.
- history of seizures, opioids, and/or hypnotic administration.
- prematurity (defined as gestational age <37 weeks)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: propofol
Propofol at a dose of 2mg/kg will be administered I.V. .
|
Intravenous induction of general anesthesia in infants 3 months or less.
|
|
Active Comparator: Sevoflurane
Sevoflurane (4%) will be used for inhalational induction.
|
Intravenous induction of general anesthesia in infants 3 months or less.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
cardiac index
Time Frame: 15 minutes
|
L/min/m2
|
15 minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MAP
Time Frame: 15 minutes
|
mmHg
|
15 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Ms_203_2021
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.